The number of adults living with diabetes has almost doubled globally since 1980, with the World Health Organization estimating that 422 million adults were living with the disease in 2014. To help address the crisis, in 2015, Dexcom, a medical device company specializing in the development of continuous glucose monitoring (CGM) systems for diabetics, released the G5 Mobile CGM System, the first to enable real-time tracking of glucose levels for adults and even young children. And Dexcom is partnering with Google’s life sciences arm, Verily, to launch a coproduced miniature CGM system next year. Dexcom’s stock price plunged in late September, however, after news that pharma giant Abbott Laboratories had received FDA approval for a rival glucose monitoring system that won’t require a pinprick.
Medical Products and Equipment
Kevin R. Sayer
San Diego, Calif.
|Revenues ($M) (Past 12 Months)||$633|
|Profits ($M) (Past 12 Months)||$-65|
|Market Value as of Oct. 9, 2017 ($M)||$4,093|